Medication with caution: Analysis of adverse reactions caused by a combination of Chinese medicine and warfarin sodium tablets. 2020

Wei Zhuang, and Ge Sun, and Xiaolan Lin, and Bin Chen, and Li Wu, and Dechun Jiang, and Shengyan Xi
Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China. Electronic address: 13522406044@163.com.

BACKGROUND With the extensive recent use of warfarin and traditional Chinese medicine (TCM) in combination, TCM has been found to affect warfarin's pharmacokinetic and pharmacodynamic parameters. Warfarin is a widely used oral anticoagulant, which has a narrow therapeutic window and a high likelihood of interacting with other drugs and resulting in serious adverse reactions. Contrary to widespread public expectations, TCM, despite being natural, is not always safe. OBJECTIVE To report the adverse drug reactions (ADR) resulting from the use of Chinese medicine and warfarin sodium tablets in combination. METHODS According to a hospital ADR monitoring report, we collected data on four clinical cases involving warfarin and single Chinese herbal medicine, warfarin and proprietary traditional Chinese medicine product, warfarin and Chinese medicinal injection, and warfarin and compound decoction. The Naranjo ADR score evaluation scale was used to analyze the relationships between warfarin and Chinese medicines. RESULTS Fluctuations in the international normalized ratio (INR) were accompanied by bleeding in some patients who regularly and simultaneously utilized warfarin and Chinese medicine. The potential risk of bleeding due to the interaction between TCM and warfarin is easily and often overlooked by both Western and TCM doctors. CONCLUSIONS Warfarin in combination with different traditional Chinese herbal medicines poses risks of INR fluctuations and adverse reactions such as bleeding. In the future, the safety awareness regarding reasonable administration of warfarin and herbal medicine should be emphasized.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004365 Drugs, Chinese Herbal Chinese herbal or plant extracts which are used as drugs to treat diseases or promote general well-being. The concept does not include synthesized compounds manufactured in China. Chinese Herbal Drugs,Plant Extracts, Chinese,Chinese Drugs, Plant,Chinese Plant Extracts,Extracts, Chinese Plant,Herbal Drugs, Chinese
D005260 Female Females
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014859 Warfarin An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one,Aldocumar,Apo-Warfarin,Coumadin,Coumadine,Gen-Warfarin,Marevan,Tedicumar,Warfant,Warfarin Potassium,Warfarin Sodium,Potassium, Warfarin,Sodium, Warfarin

Related Publications

Wei Zhuang, and Ge Sun, and Xiaolan Lin, and Bin Chen, and Li Wu, and Dechun Jiang, and Shengyan Xi
October 1976, Journal of pharmaceutical sciences,
Wei Zhuang, and Ge Sun, and Xiaolan Lin, and Bin Chen, and Li Wu, and Dechun Jiang, and Shengyan Xi
August 1997, Journal of pharmaceutical and biomedical analysis,
Wei Zhuang, and Ge Sun, and Xiaolan Lin, and Bin Chen, and Li Wu, and Dechun Jiang, and Shengyan Xi
August 2007, The Journal of pharmacology and experimental therapeutics,
Wei Zhuang, and Ge Sun, and Xiaolan Lin, and Bin Chen, and Li Wu, and Dechun Jiang, and Shengyan Xi
October 2011, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Wei Zhuang, and Ge Sun, and Xiaolan Lin, and Bin Chen, and Li Wu, and Dechun Jiang, and Shengyan Xi
January 2014, African journal of traditional, complementary, and alternative medicines : AJTCAM,
Wei Zhuang, and Ge Sun, and Xiaolan Lin, and Bin Chen, and Li Wu, and Dechun Jiang, and Shengyan Xi
February 2012, British journal of hospital medicine (London, England : 2005),
Wei Zhuang, and Ge Sun, and Xiaolan Lin, and Bin Chen, and Li Wu, and Dechun Jiang, and Shengyan Xi
February 2010, Journal of evidence-based medicine,
Wei Zhuang, and Ge Sun, and Xiaolan Lin, and Bin Chen, and Li Wu, and Dechun Jiang, and Shengyan Xi
September 2012, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Wei Zhuang, and Ge Sun, and Xiaolan Lin, and Bin Chen, and Li Wu, and Dechun Jiang, and Shengyan Xi
February 2010, Journal of evidence-based medicine,
Wei Zhuang, and Ge Sun, and Xiaolan Lin, and Bin Chen, and Li Wu, and Dechun Jiang, and Shengyan Xi
September 2007, The Annals of pharmacotherapy,
Copied contents to your clipboard!